Ceterix Orthopaedics’ NovoStitch Pro is complementary to Smith & Nephew’s FAST-FIX 360 Meniscal Repair System. Credit: Smith & Nephew.

Smith & Nephew has agreed to purchase US-based medical device developer Ceterix Orthopaedics in a bid to expand its meniscal repair portfolio.

British medical technology company Smith & Nephew will initially pay $50m in cash and up to $55m over the next five years depending on financial performance.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Ceterix Orthopaedics is focussed on meniscal preservation. Its NovoStitch Pro Meniscal Repair System is designed to help address complex meniscal tear patterns.

Surgeons can use NovoStitch Pro to arthroscopically repair a variety of meniscal tear types such as horizontal, radial, complex, bucket handle, root and vertical tears.

The device is expected to complement Smith & Nephew’s FAST-FIX 360 Meniscal Repair System, which is used for treating vertical tears.

“We are proud of the impact our technology has made in developing the meniscal repair market and are excited by the opportunity to reach many more customers.”

Smith & Nephew sports medicine and ENT president Brad Cannon said: “NovoStitch Pro is an outstanding technology that addresses an unmet clinical need.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We are excited by the opportunities to take this new option to our customers. No other company is better positioned to support changing clinical practice as the standard for meniscal treatment pivots from resection to repair.”

Smith & Nephew intends to commercialise the NovoStitch Pro device through its sports medicine sales force, as well as Ceterix Orthopaedics’ existing dedicated sales force.

Ceterix Orthopaedics CEO John McCutcheon said: “We are proud of the impact our technology has made in developing the meniscal repair market and are excited by the opportunity to reach many more customers and their patients as an integrated part of Smith & Nephew’s extensive portfolio.”

The acquisition is subject to customary conditions and is set to be completed early next year.

Smith & Nephew signed a similar agreement in October last year to takeover US-based tissue regeneration technology developer Rotation Medical.